ClearPoint Neuro logo
ClearPoint Neuro CLPT
$ 11.52 5.74%
report update icon

Quarterly report 2026-Q2
added 08-03-2026

ClearPoint Neuro Financial Statements 2025-2009 | CLPT

Annual Financial Statements ClearPoint Neuro

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

316 M 466 M 149 M 217 M 183 M 366 M 68.4 M 30 M 20.9 M 7.38 M 29.4 M 1.78 B 3.07 B 2.71 B - - -

Shares

28.3 M 27 M 24.6 M 24.2 M 20.7 M 15.5 M 13.2 M 10.9 M 7.74 M 2.75 M 1.88 M 59.2 M 57.3 M 40.4 M - 6.77 M -

Historical Prices

11.2 17.2 6.05 8.96 8.83 23.6 5.2 2.6 3 2.68 15.6 30 54.4 67.2 - - -

Net Income

-25.5 M -18.9 M -22.1 M -16.4 M -14.4 M -6.78 M -5.54 M -6.16 M -7.17 M -8.07 M -8.45 M -4.52 M -7.09 M -5.88 M -8.31 M -9.45 M -

Revenue

37 M 31.4 M 24 M 20.6 M 16.3 M 12.8 M 11.2 M 7.35 M 7.38 M 5.75 M 4.59 M 122 K 82 K 5.06 M 3.82 M 2.67 M -

Cost of Revenue

14.3 M 12.3 M 10.3 M 7.02 M 5.18 M 3.71 M 3.94 M 2.43 M 2.9 M - - - - - - - -

Gross Profit

22.7 M 19.1 M 13.6 M 13.5 M 11.1 M 9.12 M 7.38 M 4.92 M 4.48 M 3.11 M 2.61 M -1.81 M -1.34 M 4.5 M 3.16 M - -

Operating Income

-24.2 M -19.7 M -22.4 M -16.3 M -13.4 M -6.22 M -4.59 M -5.25 M -6.34 M -7.49 M -8.97 M -5.32 M -7.47 M -3.13 M -5.92 M -9.52 M -

Interest Expense

-146 K -40 K -29 K 81 K 973 K 1.44 M 955 K 980 K 873 K 1.05 M 1.26 M 1.02 M 500 K 2.59 M 2.5 M 1.59 M -

EBITDA

-23.4 M -18.8 M -21.8 M -16.1 M -13.2 M -5.67 M -4.45 M -5.14 M -6.22 M -8.14 M -8.76 M -4.61 M -6.91 M -3.4 M -5.57 M -9.25 M -

Operating Expenses

- - - - - 15.3 M 12 M 10.2 M 10.8 M 10.6 M 10.3 M 11.3 M 9.98 M 7.63 M 9.08 M - -

General and Administrative Expenses

16.5 M 12 M 11.8 M 9.61 M 8 M 5.27 M 4.3 M 4.33 M 4.05 M - - - - - - 4.7 M -

All numbers in USD currency

Quarterly Income Statement ClearPoint Neuro

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

30.2 M 29.5 M 28.4 M 28.3 M 27.7 M 27.6 M 27.6 M 27.5 M 25.5 M 24.7 M 24.6 M 24.6 M 24.6 M 24.6 M 24.5 M 24 M 23.7 M 23.7 M 22.5 M 21.5 M 18.9 M 17 M 15.7 M 15.5 M 15.4 M 15.2 M 14.1 M 12.3 M 11 M 11 M 11 M 11 M 10.7 M 10.7 M 10.3 M 6.32 M 3.62 M 3.62 M 2.78 M 1.97 M 2.29 M 2.28 M 1.87 M 74.8 M 74.8 M 74.8 M 59 M 58.9 M 58.7 M 58.5 M 58.3 M 57.4 M 54.9 M 48.1 M 47.5 M 40.6 M 25.2 M 16.1 M 16 M 15.9 M 15.9 M

Net Income

-11.3 M -9.55 M -5.89 M -5.84 M -6.03 M - -4.97 M -4.41 M -4.15 M - -4.81 M -7.05 M -5.61 M - -3.79 M -4.3 M -3.96 M - -3.98 M -3.74 M -2.54 M - -1.48 M -1.66 M -2.06 M - -1.12 M -1.55 M -1.22 M - -1.43 M -1.88 M -1.64 M - -1.43 M -2 M -1.66 M - -2.56 M -1.78 M -2.04 M - -245 K -3.06 M -3.95 M - -3.65 M -1.59 M 2.63 M - -3.19 M -1.35 M -824 K - -5.88 M -5.88 M -5.88 M - -8.31 M -8.31 M -2.25 M

Revenue

10.9 M 12.1 M 8.86 M 9.22 M 8.48 M - 8.12 M 7.86 M 7.64 M - 5.76 M 5.95 M 5.43 M - 5.15 M 5.2 M 5.03 M - 4.57 M 3.41 M 4.03 M - 3.52 M 2.48 M 12.8 M - 2.93 M 2.61 M 2.47 M - 1.81 M 1.65 M 1.62 M - 1.72 M 1.98 M 2.01 M - 1.62 M 1.1 M 1.39 M - 1.25 M 826 K 1.01 M - 633 K 1.19 M 823 K - 927 K 562 K 1.26 M - 1.13 M 1.08 M 980 K - 1.15 M 723 K 776 K

Cost of Revenue

4.17 M 4.37 M 3.26 M 3.66 M 3.35 M - 3.28 M 2.87 M 3.11 M - 2.49 M 2.82 M 2.23 M - 1.47 M 1.94 M 1.8 M - 1.53 M 1.14 M 1.42 M - 903 K 802 K 932 K - 983 K 1.03 M 886 K - 553 K 602 K 589 K - 689 K 798 K - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

6.71 M 7.76 M 5.6 M 5.56 M 5.13 M - 4.85 M 4.99 M 4.52 M - 3.27 M 3.13 M 3.2 M - 3.68 M 3.26 M 3.23 M - 3.04 M 2.27 M 2.61 M - 2.62 M 1.68 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-10.2 M -8.48 M -5.28 M -5.68 M -6.16 M - -5.16 M -4.72 M -4.22 M - -4.9 M -7.13 M -5.71 M - -3.8 M -4.2 M -3.86 M - -3.8 M -3.41 M -2.18 M - -1.27 M -1.48 M -1.21 M - -911 K -1.29 M -972 K - -1.21 M -1.64 M -1.43 M - -1.33 M -1.82 M -1.35 M - -1.71 M -2.06 M -1.93 M - -1.93 M -2.68 M -2.94 M - -2.62 M -2.22 M 2.19 M - -1.86 M -2.18 M -1.37 M - -1.02 M -3.13 M -1.15 M - -1.43 M -1.47 M -1.71 M

Interest Expense

-7 K -35 K -64 K -52 K 4 K - -11 K 5 K -26 K - -12 K -2 K -11 K - -25 K -8 K 11 K - 62 K 240 K 332 K - 201 K 197 K 842 K - 213 K 259 K 254 K - 247 K 248 K 247 K - 211 K 213 K 213 K - 240 K 251 K 345 K - 317 K 312 K 308 K - 289 K 284 K 151 K - 128 K 130 K 106 K - 85.8 K 96 K 2.33 M - 706 K 598 K 542 K

EBITDA

-10 M -8.39 M - - -6.06 M - - - -3.97 M - - - -5.58 M - -3.57 M -4.02 M -3.78 M - -3.69 M -3.34 M -2.17 M - -1.1 M -1.36 M -1.15 M - -805 K -1.22 M -938 K - -1.12 M -1.58 M -1.4 M - -1.23 M -1.76 M -1.32 M - -1.58 M -1.97 M -1.89 M - -1.77 M -2.55 M -2.86 M - -2.32 M -2.01 M 2.28 M - -1.52 M -1.95 M -1.25 M - -707 K -2.92 M -1.05 M - -1.18 M -1.33 M -1.64 M

General and Administrative Expenses

5.55 M 5 M 3.59 M 3.39 M 4.08 M - 3.14 M 2.76 M 2.83 M - 2.9 M 3.18 M 2.96 M - 2.4 M 2.66 M 2.18 M - 2.44 M 1.98 M 1.66 M - 1.25 M 1.21 M 1.28 M - 1.03 M 1.03 M 933 K - 1.08 M 1.09 M 953 K - 867 K 936 K 984 K - 1.89 M 1.89 M 1.97 M - 2.13 M 2.19 M 2.29 M - 2.06 M 1.93 M 1.8 M - 1.7 M 1.7 M 1.63 M - 1.44 M 1.8 M 1.34 M - 1.37 M 1.11 M 1.24 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ClearPoint Neuro CLPT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ClearPoint Neuro plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Orthofix Medical Orthofix Medical
OFIX
$ 9.5 4.51 % $ 376 M curacaoCuracao
Outset Medical Outset Medical
OM
$ 4.1 3.54 % $ 62.4 K usaUSA
PAVmed PAVmed
PAVM
$ 2.66 4.36 % $ 1.78 M usaUSA
Penumbra Penumbra
PEN
$ 317.11 0.07 % $ 12.3 B usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 135.62 2.98 % $ 9.54 B usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 6.03 3.25 % $ 182 M canadaCanada
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.81 4.67 % $ 162 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 13.25 4.17 % $ 369 M australiaAustralia
Sintx Technologies Sintx Technologies
SINT
$ 2.18 1.05 % $ 6.05 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 26.92 1.87 % $ 23.3 B britainBritain
Sensus Healthcare Sensus Healthcare
SRTS
$ 2.92 0.34 % $ 47.7 M usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 285.22 3.54 % $ 109 B usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 22.47 1.67 % $ 514 M usaUSA
TELA Bio TELA Bio
TELA
$ 1.14 0.88 % $ 53.5 M usaUSA
TransMedics Group TransMedics Group
TMDX
$ 82.99 4.0 % $ 2.82 B usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 16.52 0.12 % $ 1.12 B usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 9.24 1.2 % $ 359 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 18.45 0.14 % $ 764 M usaUSA
Vivos Therapeutics Vivos Therapeutics
VVOS
$ 0.15 1.52 % $ 1.54 M usaUSA
Beyond Air Beyond Air
XAIR
$ 2.84 0.71 % $ 23.6 B usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.33 0.09 % $ 46 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 91.57 3.72 % $ 18.1 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA